Due to the Controlled Substance Act of 1971, it has been challenging to secure federal funding for research on psychedelic compounds, forcing scientists to seek funding from philanthropists and write grants for unrelated work to sustain themselves. To accelerate therapeutic breakthroughs, government agencies like NIMH and NIH need to provide funding to cover clinical and basic research on psychedelic compounds.